tiprankstipranks
Trending News
More News >
Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Advertisement

Aligos Therapeutics (ALGS) AI Stock Analysis

Compare
219 Followers

Top Page

ALGS

Aligos Therapeutics

(NASDAQ:ALGS)

Rating:51Neutral
Price Target:
$8.50
▼(-8.41%Downside)
Aligos Therapeutics has a stable balance sheet but struggles with profitability and cash flow, which are typical challenges for early-stage biotech firms. The stock shows some positive momentum in technical analysis, but valuation metrics highlight significant risks. The absence of earnings call insights and corporate events means the analysis is primarily driven by financial performance, technical analysis, and valuation.
Positive Factors
Clinical Trials
The initiation of ALG-000184's randomized, double-blind, active-controlled Phase 2 study is regarded as Aligos' next major milestone.
Regulatory Support
Aligos is moving toward a more attainable goal, and one that is expected to be supported and endorsed by the FDA, EMA, and NMPA.
Therapeutic Potential
ALG-000184 showcased robust and sustained antiviral activity in both HBeAg-positive and HBeAg-negative patients with CHB, highlighting its potential as a first-line therapy for long-term viral suppression.
Negative Factors
Market Competition
ALG-000184 achieved the primary endpoint in 100% of patients in the Phase 1 study, compared to 21% for the standard-of-care treatment.

Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)

Aligos Therapeutics Business Overview & Revenue Model

Company DescriptionAligos Therapeutics (ALGS) is a clinical-stage biopharmaceutical company specializing in the development of targeted antiviral therapies for chronic liver diseases and other viral infections. The company focuses primarily on discovering and advancing small molecule and oligonucleotide-based therapeutics. Aligos's core research and development efforts are directed towards treating hepatitis B virus (HBV) infections, nonalcoholic steatohepatitis (NASH), and coronaviruses, leveraging their expertise in virology and liver disease.
How the Company Makes MoneyAligos Therapeutics generates revenue primarily through research and development partnerships, licensing agreements, and collaboration with other pharmaceutical companies. These partnerships often involve upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of successfully commercialized products. Aligos also seeks funding from government grants and other sources to support its clinical trials and research initiatives. The company’s financial performance is closely tied to the progress and outcomes of its clinical trials, regulatory approvals, and the commercial success of its developed therapies.

Aligos Therapeutics Financial Statement Overview

Summary
Aligos Therapeutics faces significant challenges in profitability, with consistent losses and negative cash flows. The balance sheet is relatively robust with low leverage, providing stability, but the ongoing cash burn rate and negative profitability metrics pose risks.
Income Statement
45
Neutral
Aligos Therapeutics shows a volatile revenue pattern with a decline to $3.27M in TTM from $15.53M in 2023. Despite improving gross profit margins, ongoing losses with a net profit margin of -1628% in TTM highlight persistent challenges in achieving profitability. The EBIT and EBITDA margins also remain negative, indicating operational inefficiencies.
Balance Sheet
55
Neutral
The balance sheet indicates a relatively stable equity position with stockholders' equity at $116.45M, although the negative net income affects ROE. The debt-to-equity ratio of 0.07 suggests low leverage, which is favorable, but the negative equity in previous years is a concern. The equity ratio stands at 77%, reflecting a strong asset base.
Cash Flow
50
Neutral
Cash flow analysis reveals negative operating cash flow of -$78.91M, with free cash flow remaining negative at -$79.01M. However, strong financing cash flow at $102.12M in TTM supports liquidity. The operating cash flow to net income ratio shows inefficiency in converting net income to cash, a risk for future operations.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue3.94M15.53M13.91M4.36M0.00
Gross Profit1.32M12.46M10.23M-99.79M-3.33M
EBITDA-89.15M-85.06M-93.91M-124.54M-105.06M
Net Income-131.21M-87.68M-96.05M-128.33M-108.54M
Balance Sheet
Total Assets70.09M151.53M146.69M235.37M265.30M
Cash, Cash Equivalents and Short-Term Investments56.94M135.70M125.83M190.73M243.51M
Total Debt8.38M11.14M12.57M14.46M13.01M
Total Liabilities99.07M59.45M42.79M50.64M45.26M
Stockholders Equity-28.97M92.08M103.90M184.73M220.04M
Cash Flow
Free Cash Flow-80.87M-79.02M-80.33M-116.55M-76.33M
Operating Cash Flow-80.74M-79.00M-79.39M-115.66M-74.26M
Investing Cash Flow-18.28M44.98M-26.29M3.02M32.76M
Financing Cash Flow355.00K88.33M164.00K78.68M192.35M

Aligos Therapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.28
Price Trends
50DMA
7.27
Positive
100DMA
7.54
Positive
200DMA
15.21
Negative
Market Momentum
MACD
0.51
Negative
RSI
57.83
Neutral
STOCH
54.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Positive. The current price of 9.28 is above the 20-day moving average (MA) of 8.28, above the 50-day MA of 7.27, and below the 200-day MA of 15.21, indicating a neutral trend. The MACD of 0.51 indicates Negative momentum. The RSI at 57.83 is Neutral, neither overbought nor oversold. The STOCH value of 54.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ALGS.

Aligos Therapeutics Risk Analysis

Aligos Therapeutics disclosed 91 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Aligos Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$268.10M-414.88%-65.96%40.80%
52
Neutral
$7.62B0.05-63.03%2.44%16.33%0.31%
51
Neutral
$56.75M-60.44%-76.29%
46
Neutral
$29.03M-70.06%146.47%57.85%
41
Neutral
$38.32M-853.05%34.97%
35
Underperform
$55.54M-280.78%68.75%
30
Underperform
$49.18M-2880.11%31.09%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ALGS
Aligos Therapeutics
9.28
-4.22
-31.26%
TVRD
Tvardi Therapeutics
27.29
14.15
107.69%
PYPD
PolyPid
3.74
0.24
6.86%
ANVS
Annovis Bio
2.85
-7.62
-72.78%
GBIO
Generation Bio
4.20
-30.00
-87.72%
NRSN
Neurosense Therapeutics Ltd.
2.03
1.22
150.62%

Aligos Therapeutics Corporate Events

Shareholder Meetings
Aligos Therapeutics Approves Major Amendments at Annual Meeting
Neutral
Jun 26, 2025

On June 25, 2025, Aligos Therapeutics, Inc. held its Annual Meeting of Stockholders where significant amendments to the company’s Certificate of Incorporation were approved. These amendments included increasing the number of authorized shares of voting common stock from 20 million to 100 million and non-voting common stock from 800,000 to 15.8 million. These changes, effective immediately upon filing with the Secretary of State of Delaware, are expected to impact the company’s capital structure significantly. Additionally, stockholders voted on five proposals, including electing three Class II directors and ratifying Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (ALGS) stock is a Buy with a $75.00 price target. To see the full list of analyst forecasts on Aligos Therapeutics stock, see the ALGS Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 10, 2025